HP
HealthInvest Partners Portfolio holdings
AUM $234M
1-Year Return
10.88%
This Quarter Return
+18.41%
1 Year Return
+10.88%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$164M
AUM Growth
+$36.6M
(+29%)
Cap. Flow
+$24M
Cap. Flow
% of AUM
14.58%
Top 10 Holdings %
Top 10 Hldgs %
53.05%
Holding
50
New
5
Increased
29
Reduced
6
Closed
6
Top Buys
| 1 |
Merck
MRK
|
+$8.98M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$4.26M |
| 3 |
Eli Lilly
LLY
|
+$3.87M |
| 4 |
Option Care Health
OPCH
|
+$3.21M |
| 5 |
Mirum Pharmaceuticals
MIRM
|
+$3.09M |
Top Sells
| 1 |
Centene
CNC
|
+$4.6M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$4.52M |
| 3 |
Cencora
COR
|
+$4.5M |
| 4 |
Cigna
CI
|
+$4.49M |
| 5 |
Gilead Sciences
GILD
|
+$3.44M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Merck
MRK
$203B
| $17.6M | 10.74% |
133,741
+68,066
| +104% | +$8.98M |
|
|
2
Eli Lilly
LLY
$676B
| $16.2M | 9.84% |
20,778
+4,973
| +31% | +$3.87M |
|
3
UnitedHealth
UNH
$312B
| $11.4M | 6.94% |
23,041
+4,633
| +25% | +$2.29M |
|
4
Thermo Fisher Scientific
TMO
$180B
| $8.83M | 5.37% |
15,186
+3,771
| +33% | +$2.19M |
|
|
5
Neurocrine Biosciences
NBIX
$14B
| $6M | 3.65% |
43,480
+30,863
| +245% | +$4.26M |
|
6
Harmony Biosciences
HRMY
$1.87B
| $5.71M | 3.47% |
170,000
+25,000
| +17% | +$840K |
|
7
Stryker
SYK
$144B
| $5.42M | 3.3% |
15,154
+2,352
| +18% | +$842K |
|
8
Amgen
AMGN
$149B
| $5.37M | 3.27% |
18,891
+2,868
| +18% | +$815K |
|
9
AbbVie
ABBV
$385B
| $5.34M | 3.25% |
29,346
+8,150
| +38% | +$1.48M |
|
10
Boston Scientific
BSX
$148B
| $5.3M | 3.23% |
77,401
+12,595
| +19% | +$863K |
|
11
Regeneron Pharmaceuticals
REGN
$61B
| $5.19M | 3.16% |
5,393
+1,414
| +36% | +$1.36M |
|
|
12
Cencora
COR
$56.5B
| $4.96M | 3.02% |
20,426
-18,499
| -48% | -$4.5M |
|
13
Molina Healthcare
MOH
$9.59B
| $4.93M | 3% |
12,000
-500
| -4% | -$205K |
|
14
Vertex Pharmaceuticals
VRTX
$101B
| $4.72M | 2.87% |
11,295
+2,165
| +24% | +$905K |
|
|
15
Option Care Health
OPCH
$4.52B
| $4.46M | 2.71% |
132,895
+95,672
| +257% | +$3.21M |
|
16
Elevance Health
ELV
$69.5B
| $3.84M | 2.33% |
7,400
-2,100
| -22% | -$1.09M |
|
|
17
Gilead Sciences
GILD
$141B
| $3.81M | 2.32% |
52,000
-46,974
| -47% | -$3.44M |
|
18
DexCom
DXCM
$29.9B
| $3.65M | 2.22% |
26,283
+8,226
| +46% | +$1.14M |
|
|
19
Mirum Pharmaceuticals
MIRM
$3.76B
| $3.09M | 1.88% |
+123,000
| New | +$3.09M |
|
20
Cardinal Health
CAH
$36B
| $3.08M | 1.87% |
27,500
-20,500
| -43% | -$2.29M |
|
21
Amicus Therapeutics
FOLD
$2.4B
| $2.97M | 1.81% |
252,307
+203,597
| +418% | +$2.4M |
|
|
FUSN
22
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $2.96M | 1.8% |
138,836
+13,836
| +11% | +$295K |
|
23
Ionis Pharmaceuticals
IONS
$9.74B
| $2.77M | 1.68% |
63,791
+39,548
| +163% | +$1.71M |
|
24
Immunocore
IMCR
$1.73B
| $2.66M | 1.62% |
40,899
+33,076
| +423% | +$2.15M |
|
|
ITCI
25
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $2.63M | 1.6% |
38,050
+25,805
| +211% | +$1.79M |
|